Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | BRS3 | P32247 | 4/20 | 0.35 |
| ▸ | WNT3A | P56704 | 2/20 | 0.34 |
| ▸ | PTGES | O14684 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.32 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9948774 | 1.00 | TSHR (0.36) | TSHRS1PR1BRS3WNT3APTGES | |
| SCHEMBL15869628 | 0.91 | TSHR (0.35) | TSHRS1PR1BRS3WNT3APTGES | |
| SCHEMBL9947939 | 0.90 | TSHR (0.38) | TSHRS1PR1BRS3WNT3AFAAH | |
| SCHEMBL9947933 | 0.90 | TSHR (0.38) | TSHRS1PR1BRS3WNT3AFAAH | |
| SCHEMBL9947942 | 0.90 | TSHR (0.38) | TSHRS1PR1BRS3WNT3AFAAH | |
| SCHEMBL9947916 | 0.89 | TSHR (0.40) | TSHRS1PR1BRS3WNT3AFAAH | |
| SCHEMBL9947923 | 0.89 | TSHR (0.40) | TSHRS1PR1BRS3WNT3AFAAH | |
| SCHEMBL9947919 | 0.89 | TSHR (0.40) | TSHRS1PR1BRS3WNT3AFAAH | |
| SCHEMBL15869687 | 0.81 | TSHR (0.37) | TSHRS1PR1WNT3AL3MBTL1FAAH | |
| SCHEMBL15418230 | 0.81 | TSHR (0.38) | TSHRS1PR1BRS3WNT3AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2484675-A1 | NOVEL PHENYLPYRIDINE DERIVATIVE AND MEDICINAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20120165353-A1 | NOVEL PHENYLPYRIDINE DERIVATIVE AND MEDICINAL AGENT COMPRISING SAME | KOWA COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165353-A1 | NOVEL PHENYLPYRIDINE DERIVATIVE AND MEDICINAL AGENT COMPRISING SAME | AGTR2, AGTR1, PPARD | TSHR 461/4885S1PR1 1082/4885BRS3 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.